Published in J Pharmacol Exp Ther on February 23, 2015
Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation. J Pharmacol Exp Ther (2016) 0.81
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicol Sci (2016) 0.78
Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury. J Pharm Sci (2016) 0.77
Fluid Dynamic Modeling to Support the Development of Flow-Based Hepatocyte Culture Systems for Metabolism Studies. Front Bioeng Biotechnol (2016) 0.75
Prediction of Hepatic Efflux Transporter-mediated Drug Interactions: When is it Optimal to Measure Intracellular Unbound Fraction of Inhibitors? J Pharm Sci (2017) 0.75
Bile acids: regulation of synthesis. J Lipid Res (2009) 4.31
Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology (1999) 2.61
The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med (2000) 2.31
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
Bile-acid-induced cell injury and protection. World J Gastroenterol (2009) 2.06
Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol In Vitro (2006) 1.95
Bile Acids: The Good, the Bad, and the Ugly. News Physiol Sci (1999) 1.81
Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev (2004) 1.64
Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev (2010) 1.52
Bile acids and signal transduction: role in glucose homeostasis. Cell Signal (2008) 1.45
Contractility of bile canaliculi: implications for liver function. Science (1981) 1.31
Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol (2005) 1.30
Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol (2001) 1.25
Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol (2005) 1.23
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos (2011) 1.22
Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther (2007) 1.22
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci (2010) 1.22
Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology (1997) 1.22
Bile salts and cholestasis. Dig Liver Dis (2010) 1.16
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci (2013) 1.11
Cultured rat hepatocytes. Pharm Biotechnol (1996) 1.10
Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res (2008) 1.07
Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int (2007) 1.05
OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. Front Biosci (Landmark Ed) (2009) 1.05
A study of bile canalicular contractions in isolated hepatocytes. Hepatology (1983) 1.04
Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos (2008) 1.00
Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm (2007) 1.00
Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res (2002) 0.99
Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharm Res (1998) 0.97
Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J Pharmacol Exp Ther (2013) 0.96
Motility of bile canaliculi in the living animal: implications for bile flow. J Cell Biol (1991) 0.95
Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. Annu Rev Pharmacol Toxicol (2013) 0.95
Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos (2013) 0.93
Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation. J Pharmacol Exp Ther (2009) 0.93
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci (2013) 0.92
Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos (2011) 0.92
Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol Sci (2010) 0.92
Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes. Drug Metab Dispos (2011) 0.92
Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver. Pharm Res (2001) 0.84
Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification. Clin Pharmacol Ther (2012) 0.82
Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes. Toxicol Lett (2010) 0.79
Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J Pharmacol Exp Ther (2013) 0.96
Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue. Drug Metab Dispos (2013) 0.87